VIRIOS THERAPEUTICS
Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases. The company is driven to improve patient outcomes by finally answering an underlying cause of fibromyalgia and related conditions. The overactive immune response related to activation of tissue-resident Herpes Simplex Virus-1 (HSV-1) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatig... ue syndrome (CFS), and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of the disease. Virios Therapeutics' IMC-1, is a combination of antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral-mediated disease burden. In a Phase 2a proof-of-concept trial for fibromyalgia, IMC-1 provided statistically significant improvement versus placebo in the primary endpoint of pain reduction. The company plans to enter a Phase 2b trial in the 1Q21, with topline data expected in the 1Q22. Virios Therapeutics was founded in 2012 and is headquartered in Alpharetta, Georgia.
VIRIOS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Mobile Apps Therapeutics
Founded:
2012-01-01
Address:
Alpharetta, Georgia, United States
Country:
United States
Website Url:
http://www.virios.com
Total Employee:
51+
Status:
Active
Contact:
866-620-8655
Email Addresses:
[email protected]
Total Funding:
12.94 M USD
Technology used in webpage:
Euro Google Font API Google Analytics Amazon Google Analytics 4 Apache US Privacy User Signal Mechanism PostalAddress Schema Amazon S3 Amazon S3 CDN
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Molecular Templates
Molecular Templates develops novel therapeutic compounds for cancer.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Employees Featured
Founder
Stock Details
Investors List
William Buchalter
William Buchalter investment in Seed Round - Virios Therapeutics
Official Site Inspections
http://www.virios.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.36 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Virios Therapeutics"
Virios Therapeutics - Crunchbase Company Profile & Funding
Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases. View contacts for Virios Therapeutics to access …See details»
Fibromyalgia - Root Causes, Symptoms, Treatment | Virios
Pipeline - Virios
Virios’ novel FM development candidate, IMC-1, demonstrated exemplary safety and tolerability in the FORTRESS study (a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of over 400 FM patients), but did not …See details»
Virios Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Last update 01 Nov 2024. Virios Therapeutics, Inc.See details»
Virios Therapeutics Announces Publication of International Patent …
Mar 26, 2024 Virios Therapeutics - New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune …See details»
Virios Therapeutics Announces Plans to Advance Lead
Aug 9, 2023 Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral …See details»
Virios Therapeutics Announces Publication of International Patent …
Mar 26, 2024 Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a …See details»
Learn more about Virios Therapeutics : r/HerpesCureAdvocates
HCA is a grassroots, international advocacy organization with a goal of treatment, prevention, and cure for Herpes Simplex Virus types 1 + 2. www.herpescureadvocacy.com ... I think it is good …See details»
Virios Therapeutics Announces Research Collaboration Exploring …
Feb 28, 2022 According to the World Health Organization, COVID-19 has caused more than 373 million infections and more than 5.6 million deaths as of January 2022. ... Virios Therapeutics, …See details»
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 ...
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel …See details»
Meet Dr. Mike Gendreau, Virios Therapeutics Chief Medical Officer
Jan 12, 2022 R. Michael Gendreau, M.D., Ph.D. is the current Chief Medical Officer of Virios Therapeutics, a role he has held since December of 2020. Dr. Gendreau is a world-renowned …See details»
Virios Therapeutics Announces First Quarter 2024 Financial
May 9, 2024 --Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including …See details»
Virios Therapeutics, Inc. | AP News
Virios Therapeutics, Inc. The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of …See details»
Virios Therapeutics Announces Plans to Advance - GlobeNewswire
Jan 22, 2024 Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a …See details»
Virios Therapeutics Announces Research Collaboration Exploring …
Feb 28, 2022 Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, …See details»
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 ...
Mar 14, 2023 As of December 31, 2022, Virios Therapeutics’ cash totaled $7.0 million. The Company believes it will have sufficient resources to support the Long-COVID exploratory …See details»
NEWS - Virios
Apr 5, 2020 Virios Therapeutics, (Formerly Innovative Med Concepts) Builds Out Leadership Team to Scale Capital and Prepare to Execute Landmark IMC-1 Phase 2b Fibromyalgia …See details»
Virios Therapeutics (VIRI) Earnings Date and Reports 2025
Nov 29, 2024 Virios Therapeutics (NASDAQ:VIRI) has a recorded net income of -$5.30 million. VIRI has generated -$0.27 earnings per share over the last four quarters. What is Virios …See details»
Virios Therapeutics Announces First Quarter 2022 ... - Business Wire
May 12, 2022 Virios Therapeutics management will host a webcast and conference call on May 12, 2022, at 8:30 a.m. ET to discuss the Company’s financial results and provide a corporate …See details»